IFNG and neoplasm: The chimeric-antigen-receptor-tumor-induced-vector (CARTIV) platform, based on promoter-responsive elements (PREs) of gamma interferon (IFN-γ), tumor necrosis factor α (TNF-α), and hypoxia, exhibits synergistic activity in cell lines and effective activation in T cells without loss of safety [20].